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A brain-targeting lipidated peptide 
for neutralizing RNA-mediated 
toxicity in Polyglutamine Diseases
Qian Zhang1, Mengbi Yang2, Kasper K. Sørensen3, Charlotte S. Madsen3, Josephine T. 
Boesen3, Ying An1, Shao Hong Peng1, Yuming Wei1, Qianwen Wang2, Knud J. Jensen3,  
Zhong Zuo2, Ho Yin Edwin Chan1,4 & Jacky Chi Ki Ngo1
Polyglutamine (PolyQ) diseases are progressive neurodegenerative disorders caused by both protein- 
and RNA-mediated toxicities. We previously showed that a peptidyl inhibitor, P3, which binds 
directly to expanded CAG RNA can inhibit RNA-induced nucleolar stress and suppress RNA-induced 
neurotoxicity. Here we report a N-acetylated and C-amidated derivative of P3, P3V8, that showed a 
more than 20-fold increase in its affinity for expanded CAG RNA. The P3V8 peptide also more potently 
alleviated expanded RNA-induced cytotoxicity in vitro, and suppressed polyQ neurodegeneration 
in Drosophila with no observed toxic effects. Further N-palmitoylation of P3V8 (L1P3V8) not only 
significantly improved its cellular uptake and stability, but also facilitated its systemic exposure 
and brain uptake in rats via intranasal administration. Our findings demonstrate that concomitant 
N-acetylation, C-amidation and palmitoylation of P3 significantly improve both its bioactivity and 
pharmacological profile. L1P3V8 possesses drug/lead-like properties that can be further developed into 
a lead inhibitor for the treatment of polyQ diseases.
Polyglutamine (PolyQ) diseases, including Machado-Joseph Disease (MJD) and Huntington’s disease, are a group 
of dominantly inherited progressive neurodegenerative diseases characterized by the existence of expanded CAG 
trinucleotide repeats within the coding region of disease genes1. Through transcription and translation, disease 
proteins carrying an extended polyQ stretch are detected in the affected tissues. It is widely accepted that polyQ 
disease toxicity is ascribed to the misfolding and aggregation of disease proteins2–4. However, an accumulation 
of evidence demonstrates that the expanded CAG-repeat RNA also contributes to toxicity in polyQ diseases5–8. 
Various expanded CAG RNA pathogenic pathways have recently been described, including the recruitment of 
muscleblind-like (MBNL) proteins to expanded CAG-repeat RNA foci9,10, the generation of small CAG RNAs via 
Dicer cleavage11,12, and the activation of nucleolar stress13,14.
We previously demonstrated that expanded CAG RNA triggers nucleolar stress and eventually induces tox-
icity both in vitro and in vivo13,14. Nucleolar stress is a cellular response to the failure in ribosome biogenesis 
and/or ribosome malfunction15. A reduction in ribosomal RNA (rRNA) transcription causes an imbalance in 
the intracellular levels of ribosomal RNAs and ribosomal proteins, which triggers ribosome assembly defects 
and eventually leads to nucleolar stress-induced apoptosis16,17. Our previous investigation showed that expanded 
CAG RNA physically interacts with the nucleolin (NCL) protein13, a multifunctional nucleolar protein that plays 
critical roles in precursor rRNA (pre-rRNA) transcription18, processing19 and pre-ribosome assembly18,20. This 
RNA-protein interaction leads to upstream control element (UCE) hypermethylation and the down-regulation 
of rRNA transcription, which induces nucleolar stress13. We developed a 13-amino acid peptide inhibitor, P3, 
which can inhibit NCL-expanded CAG RNA interaction and suppress RNA toxicity in polyQ diseases21. The P3 
peptide was designed based on the structure of the RRM2 domain of NCL21 which contains the ribonucleopro-
tein domain-1 (RNP-1) motif22. Our study showed that P3 could directly and preferentially bind to expanded 
continuous CAG-repeat RNA in vitro21. This P3-CAG RNA interaction titrated endogenous NCL away from 
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binding to the toxic RNA and restored NCL-UCE interaction and pre-45s rRNA transcription21. Treatment of 
P3 suppressed expanded CAG RNA-induced cell death in a mammalian cell model and neurodegeneration in a 
Drosophila disease model21. The calculated maximal inhibitory concentration (IC50) of P3 in inhibiting cell death 
was 4.369 ± 1.140 μM21. In this study, we engineered peptide P3 and identified a more potent inhibitor for target-
ing RNA toxicity in polyQ diseases.
Results
Alanine scanning of P3. P3 is derived from the primary structure of NCL21. We previously synthesized 
a series of P3 analogues, in which basic or aromatic residues were substituted with Ala and their binding to 
expanded CAG RNA was measured to identify the amino acid side chains involved in the interaction with 
expanded CAG RNA. Our results showed that Lys3, Lys5, Tyr9, and Phe12 are indispensable and serve as the 
pharmacophores for RNA binding21. To further illustrate how the mutations affect the interaction between P3 and 
RNA, we performed isothermal titration calorimetry (ITC) experiments to characterize the interaction between 
each individual mutant (Supplementary Table S1) and expanded CAG RNA. All ITC experiments were performed 
using high ratios of peptide-to-RNA concentrations to increase the experiment’s sensitivity. The heat generated 
by peptide dilution was determined by titrating the peptides into buffer only and was then subtracted from the 
binding titration curves of the corresponding peptides. The determined equilibrium dissociation constant KD of 
P3 is ~8.4 µM with both favorable enthalpy (ΔH = −4.5 kcal/mol) and entropy (TΔS = 2.4 kcal/mol), suggesting 
that the peptide-RNA interaction is energetically driven by both favorable enthalpic and entropic components.
On the other hand, the determined equilibrium dissociation constant KD of P3MT3 and P3MT4 revealed 
that the mutations of the aromatic residues reduced the binding affinity to 16 and 17 μM respectively, whereas 
mutations of the lysines (P3MT1, P3MT2 and P3MT5) had a more dramatic effect and reduced the affinity by 
~3–12 fold (Supplementary Table S1). In particular, the KD of P3MT2 and P3MT5 were increased to 100 µM and 
51 µM respectively, indicating that among all the identified pharmacophores, Lys5 and Lys13 are most critical for 
RNA binding.
Amino acid substitutions of P3. The observation that favorable entropic change contributes to P3 inter-
action with expanded CAG RNA suggests that the peptide may have undergone conformational changes upon 
binding to RNA. Structure prediction of the P3 peptide using the PEP-FOLD server23 suggested that although P3 
does not adopt a well-defined tertiary structure, it may preferentially adopt a loosely folded coil conformation 
that positions the pharmacophores Lys3, Tyr9, and Phe12 on the same surface of the peptide, which may in turn 
facilitate the recognition and interaction of RNA (Supplementary Fig. S1). Such conformation is maintained par-
tially by a network of interaction mediated by the side chain of Asp1. To test whether the orientation of Asp1 is 
important, we restricted it by substituting Gly2 with D-alanine (P3V1). Our result shows that the binding affinity 
of P3V1 was improved by 4-fold which gave a KD of 2 µM. Such improvement could be due to better stabilization 
of the RNA-interacting surface via the restriction of Asp1 or because the replacement of Gly by D-Ala minimized 
the entropic loss upon binding by restricting the flexibility of the peptide. Analysis of the ITC results reveals that 
the change in the Gibbs free energy of P3V1 mainly originated from a favorable gain in enthalpy, indicating that 
the former scenario is more likely. Considering that both Phe12 and Lys13 are important for RNA binding, we 
kept the 13-mer P3 as our minimal construct for further studies.
To improve the binding affinity and specificity of P3 toward expanded CAG RNA, we performed amino acid 
substitutions at individual pharmacophores using natural amino acids with similar properties, i.e. Tyr and Phe 
to other aromatic side chains; Lys to Arg (Table 1). Substitution of Tyr9 with the larger Trp side chain (P3V2) 
resulted in a lower KD of 2.2 µM and the substitution of Phe with less hydrophobic Tyr (P3V3) and Trp (P3V4) 
also improved the binding of peptide to expanded CAG RNA by nearly 2- to 4-fold, respectively. These results 
indicate that although alterations of the size or polarity of the aromatic residues improved the binding affinity 
of P3, only modest improvements were obtained. On the other hand, the KD value of P3V5, in which Lys3 and 
Lys5 both mutated to Arg residues, was approximately 0.86 µM, reflecting a nearly 10-fold improvement over the 
P3 peptide. Contrarily, when we mutated all three Lys to Arg (P3V6), the KD of the peptide increased to 23 µM, 
indicating that the replacement of the amine of Lys13 with a guanidinium is not favored.
Termini modifications improve P3 activity. Next, we explored whether modifications at the N- and 
C-termini could improve the binding and inhibitory activity of P3. N-terminal acetylation and C-terminal ami-
dation neutralize the charges at both ends of the peptide and we speculated that it may increase its biologi-
cal activity. The C-terminal amide was incorporated by solid-phase synthesis of the peptide on a Rink amide 
linker, while the N-terminal modifications were introduced after assembly of the peptide and before acidolytic 
release of the completed structure. The KD value of P3V7 was determined to be 2 µM using ITC, indicating that 
C-terminal amidation improved the peptide affinity to expanded RNA. When the N-terminus was also acetylated, 
the dissociation constant of P3V8 was further lowered to 0.33 µM (Table 1). Based on these observations, we 
further synthesized P3V9, which combined the modifications of P3V8 and P3V5 (N-acylation, C-amidation and 
Lys-to-Arg mutation) with the hope to further improving the binding affinity of the peptide. To our surprise, the 
binding affinity of the new peptide was not improved, as the KD value was 2.3 µM (Table 1). We next investigated 
whether substitution of Lys3 and Lys5 with other non-natural Lys and Arg analogs would improve the activity 
of P3V8. The homologated Arg analog, homoarginine (hArg), and two shortened Lys analogs, ornithine (Orn) 
and 2,3-diaminopropionic acid (Dap), were used for substitution in our studies (Supplementary Table S2, P3 
variants 14–19 respectively). Our results reveal that when either Lys3 or Lys5 was replaced by any of the amino 
acid analogs, no binding could be detected between the P3 variant and the expanded CAG RNA using ITC. This 
indicates that the chain length of Lys in P3V8 is crucial for its bioactivity. In addition, the linear dimer of P3V8, 
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which has two copies of the peptide in close vicinity, did not show any binding (Supplementary Table S2, P3V20 
and P3V21). The abolishment of the bioactivity may be due to steric hindrance.
To test whether P3V8 specifically targets expanded CAG RNA, ITC experiments were performed using 
unexpanded CAG RNA (MJDCAG27 RNA), expanded CAG RNA (MJDCAG78 RNA), and expanded CAA/G RNA 
(MJDCAA/G78 RNA), respectively, to investigate whether the binding of P3V8 is RNA expansion-dependent and 
sequence-dependent (Supplementary Table S3). Our results demonstrate that P3V8 bound unexpanded RNA 
or expanded CAA/G RNA with nearly 6–9-fold lower affinity, which indicates that P3V8 is expanded CAG 
RNA-specific.
P3 derivatives showed improved suppressive effects on polyglutamine neurodegeneration in 
vivo. Given that P3V5 and P3V8 bind expanded CAG RNA with significantly higher affinities than P3, we 
next tested their inhibitory activities against polyQ neurodegeneration in vivo. We previously demonstrated that 
the full-length MJDCAG transgenic Drosophila model, flMJDCAG27/84, can be used to investigate the suppression 
effects of synthetic peptide inhibitors on both expanded RNA and polyQ protein toxicities21. Here we utilized 
the DsRedCAG0/100 Drosophila model to investigate the suppressive effects of the P3 analogs on RNA toxicity. In 
this model, the CAG repeat is located in the 3′ untranslated region of the DsRed reporter gene7. The transcribed 
expanded CAG RNA is not translated into polyQ protein, and thus the toxicity is solely attributed to the expres-
sion of DsRedCAG100 RNA. In brief, the expression of expanded CAG RNA causes severe retinal degeneration in the 
animal that can be quantified by a pseudopupil assay7. Inhibitors that can suppress neurotoxicity will result in the 
recovery of the number of rhabdomeres within the ommatidium. To test our derivatives, third instar larvae were 
fed different amounts of peptide dissolved in sucrose solution for 2 hr and then allowed to culture in standard fly 
food until the flies were 12 days old, at which time they were sacrificed for the pseudopupil assay. We observed 
that treatment with 50 µM of P3 peptide moderately suppressed neurotoxicity in DsRedCAG100 flies (pseudopupil 
score, 3.74 ± 0.05; Fig. 1a and b). In contrast, derivatives P3V5 and P3V8 both significantly suppressed neuro-
toxicity and recovered the number of rhabdomeres with much greater efficiency (Fig. 1c–f). In particular, P3V8 
displayed a high level of potency against the neurotoxicity in DsRedCAG100 flies and achieved a pseudopupil score 
of 4.32 ± 0.25 in comparison to P3V5’s score of 3.64 ± 0.22 after 1 µM treatment (Fig. 1d and f). Based on the 
results from the ITC experiments and pseudopupil assay, the peptide derivative P3V8 seems to be the most potent 
P3 variant that exerts inhibitory activity against expanded CAG RNA-induced neurotoxicity.
P3V8 restored the expression level of pre-rRNA in a fly model expressing expanded CAG 
RNA. Ribosomal RNA (rRNA) synthesis occurs within the nucleolus15. We previously showed that expanded 
CAG RNA induces nucleolar stress by preventing the nucleolar protein NCL from binding to the upstream con-
trol element of the rRNA promoter, leading to the downregulation of rRNA transcription13. To investigate whether 
P3V8 suppressed neurotoxicity by alleviating expanded CAG RNA-induced nucleolar stress in vivo, we measured 
the expression levels of pre-rRNA in DsRedCAG100 flies treated with the peptide. Real-time PCR analysis showed 
that P3V8 could restore the transcript level of pre-rRNA in a dose-dependent manner. When DsRedCAG100 flies 
were treated with 1 μM of P3V8, the pre-rRNA level was fully recovered to the DsRedCAG0 control level (Fig. 2). 
This confirms that P3V8 subdued polyQ neurodegeneration in vivo by effective mitigation of the expanded CAG 
RNA-induced nucleolar stress.
Peptide Sequence KD (μM)
P3WT Asp-Gly-Lys-Ser-Lys-Gly-Ile-Ala-Tyr-Ile-Glu-Phe-Lys 8.37 ± 3.83
P3 variant 
1 (P3V1) Asp-{d-Ala}-Lys-Ser-Lys-Gly-Ile-Ala-Tyr-Ile-Glu-Phe-Lys 2.00 ± 0.34
P3 variant 
2 (P3V2) Asp-Gly-Lys-Ser-Lys-Gly-Ile-Ala-Trp-Ile-Glu-Phe-Lys 2.21 ± 1.27
P3 variant 
3 (P3V3) Asp-Gly-Lys-Ser-Lys-Gly-Ile-Ala-Tyr-Ile-Glu-Tyr-Lys 1.74 ± 0.67
P3 variant 
4 (P3V4) Asp-Gly-Lys-Ser-Lys-Gly-Ile-Ala-Tyr-Ile-Glu-Trp-Lys 4.44 ± 0.47
P3 variant 
5 (P3V5) Asp-Gly-Arg-Ser-Arg-Gly-Ile-Ala-Tyr-Ile-Glu-Phe-Lys 0.86 ± 0.17
P3 variant 
6 (P3V6) Asp-Gly-Arg-Ser-Arg-Gly-Ile-Ala-Tyr-Ile-Glu-Phe-Arg 23.78 ± 2.78
P3 variant 
7 (P3V7) Asp-Gly-Lys-Ser-Lys-Gly-Ile-Ala-Tyr-Ile-Glu-Phe-Lys-NH2 3.67 ± 0.26
P3 variant 
8 (P3V8) Ac-Asp-Gly-Lys-Ser-Lys-Gly-Ile-Ala-Tyr-Ile-Glu-Phe-Lys-NH2 0.33 ± 0.04
P3 variant 
9 (P3V9) Ac-Asp-Gly-Arg-Ser-Arg-Gly-Ile-Ala-Tyr-Ile-Glu-Phe-Lys-NH2 2.34 ± 0.49
Table 1. Binding affinity of P3V1-9 expanded MJDCAG78 RNA. P3WT or P3 variants (0.7 mM) were titrated into 
MJDCAG78 RNA (0.5 µM) and the thermal titration data were fitted to the ‘one binding site model’ to determine 
the dissociation constant (KD). WT indicates wild type. Data are expressed as mean ± S.E.M. for at least 3 
independent experiments.
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P3V8 suppressed expanded CAG RNA-induced cell death by modulating rRNA transcription 
in vitro. We next investigated whether P3V8 could also mitigate expanded CAG RNA-induced toxicity in 
mammalian cells. Overexpression of EGFPCAG78 RNA in HEK293 cells has been shown to induce nucleolar stress 
and apoptosis21. To compare the inhibitory activity of P3WT and P3V8, we used the peptide transfection reagent 
DeliverX (DX) to deliver P3WT and P3V8 to EGFPCAG78 RNA-expressing HEK293 cells. Figure 3a shows that irre-
spective of the addition of DX transfectant, treatment of P3WT lower than 1 µΜ did not elicit any significant sup-
pression effect on expanded CAG RNA-induced cell death. Although P3V8 alone did not exert any cellular effect, 
its administration with the aid of DX could effectively alleviate the cytotoxicity induced by expanded CAG RNA 
(Fig. 3b). To confirm that P3V8 inhibited expanded CAG RNA-mediated nucleolar stress, we measured the levels 
of pre-45s rRNA in EGFPCAG78 RNA-expressing cells with or without treatment of P3V8 (Fig. 3c). Overexpression 
of the expanded CAG RNA reduced the level of pre-45s rRNA to approximately 40% of the untransfected control. 
Figure 1. P3V8 most effectively suppresses expanded CAG RNA-induced RNA toxicity in vivo. (a) Effect of 
P3WT on suppressing DsRedCAG100 neurodegeneration in Drosophila. (b) Statistical analysis of panel (a). (c) 
Effect of P3V5 on suppressing DsRedCAG100 neurodegeneration in Drosophila. (d) Statistical analysis of panel (c). 
(e) Effect of P3V8 on suppressing DsRedCAG100 neurodegeneration in Drosophila. (f) Statistical analysis of panel 
(e). Pseudopupil assay was performed on 12 day-old adult flies. The flies were of genotypes w; gmr-GAL4 UAS-
DsRedCAG0/+; +/+ and w; gmr-GAL4/+; UAS-DsRedCAG100/+. Data are expressed as mean ± S.E.M. for at least 3 
independent experiments. *Indicates P < 0.05, **indicates P < 0.01 and ***indicates P < 0.001.
www.nature.com/scientificreports/
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Figure 2. Treatment of P3V8 peptide suppresses nucleolar stress in vivo. Treatment of P3V8 restored pre-
rRNA levels in DsRedCAG100 flies. Real-time PCR was performed to determine the levels of pre-rRNA. Data are 
presented as fold change of the relative pre-rRNA expression levels compared with the blank. Experiments were 
repeated at least 3 times, and data are expressed as mean ± S.E.M. *Indicates P < 0.05 and **indicates P < 0.01.
Figure 3. P3V8 effectively inhibits cytotoxicity induced by expanded CAG RNA in vitro. (a) Dose-dependent 
effect of synthetic P3WT in the absence or presence of DeliverX on the inhibition of cell death in EGFPCAG78 
RNA-expressing HEK293 cells. (b) Dose-dependent effect of synthetic P3V8 in the absence or presence of 
DeliverX on the inhibition of cell death in EGFPCAG78 RNA-expressing HEK293 cells. Left of the charts: various 
amount of P3WT (a) or P3V8 (b) were transfected into individual culture wells by DeliverX 4 hr after plasmid 
transfection. Right of the charts: P3WT (a) or P3V8 (b) was added into individual culture wells immediately 
after plasmid transfection. A lactate dehydrogenase (LDH) cytotoxicity assay was performed. (c) Treatment 
of P3V8 (with DeliverX) restored pre-45s rRNA levels in EGFPCAG78 RNA-expressing HEK293 cells. Cells were 
transfected with various amount of P3V8 using DeliverX. Data are presented as fold change of the relative pre-
45s rRNA expression levels compared with the untransfected samples. Experiments were repeated at least 3 
times and data are expressed as mean ± S.E.M. NS indicates no significance. *Indicates P < 0.05, **indicates 
P < 0.01, ***indicates P < 0.001 and ****indicates P < 0.0001.
www.nature.com/scientificreports/
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Upon P3V8 treatment, a dose-dependent restoration of pre-45s rRNA level was observed (Fig. 3c). Taken together, 
our results demonstrate that P3V8 could effectively mitigate expanded CAG RNA-induced nucleolar stress and 
neutralize the cytotoxic effect.
Assessment of P3V8 toxicity. Because we aim to develop P3V8 into a potent inhibitor that targets RNA 
toxicity in degenerating cells within the nervous system, we assessed whether P3V8 had deleterious effects on 
neuronal cells by determining lactate dehydrogenase release in the culturing medium of rat cortical neurons. 
After incubation of P3V8 in concentrations ranging from 0.01 nM to 1 µM for 72 hr, no significant cell death 
was observed in the P3V8-treated neurons when compared to the untreated control (Supplementary Fig. S2). It 
should be noted that the peptide also did not show any observable effect when DsRedCAG0 Drosophila was treated 
with P3V8 at up to 50 µM (Fig. 1e and f). This indicates that P3V8 exhibits low cytotoxicity both in vitro and in 
vivo.
N-terminally acylated P3V8 showed enhanced cellular uptake. Acylation of peptides with 
long-chain lipids has been shown to improve their cellular uptake, in vivo half-life, and membrane permeability 
and to change their pharmacokinetic properties24–26. Importantly, lipid solubility is a key factor for the transpor-
tation of inhibitors across the blood-brain barrier. We therefore investigated whether acylation of P3V8 could 
improve its cellular uptake in vitro as well as bioavailability both in vitro and in vivo. The L1P3V8 peptide was 
generated by introducing palmitic acid N-terminally to P3V8 in place of N-acetylation (Fig. 4a). LC/MS was 
used to detect the level of P3V8 or L1P3V8 uptaken by HEK293 cells after 3 hr treatment. Figure 4b shows that 
higher cellular concentration of L1P3V8 was measured in HEK293 cells when compared to that of P3V8 in both 
500 nM and 1 µM treatment groups. While we could detect a low cellular concentration of L1P3V8 in HEK293 
cells treated with 100 nM of peptide, no uptake of P3V8 was detected (Fig. 4b). These data collectively demon-
strated that the lipidation of P3V8 improved peptide cellular uptake. We next administered L1P3V8 to EGFPCAG78 
RNA-expressing HEK293 cells without any DX peptide transfecting reagents to determine whether lipidation 
can facilitate the cellular uptake of the peptide. As shown in Fig. 4c, L1P3V8 alone effectively inhibited expanded 
CAG RNA-induced cell death with an empirical IC50 value of ~100 nM. In addition, L1P3V8 showed no cyto-
toxic effects on rat cortical neurons and DsRedCAG0 Drosophila model, and no obvious alteration in egg-to-adult 
viability of wild type flies (Supplementary Figs S3 and S4 and Fig. 4d). Treatment of DsRedCAG100 Drosophila with 
L1P3V8 also suppressed retinal degeneration (Fig. 4d and e). These findings indicate that lipidation of P3V8 
improved its cell penetration properties without affecting its inhibitory activity.
Lipidation improved P3V8 in vitro stability. To test whether lipidation could also improve the stability 
of P3V8, we compared the stabilities of P3V8 and L1P3V8 in rat plasma and brain homogenate via in vitro incu-
bation to estimate their extent of degradation in plasma and brain tissues. The results shown in Table 2 indicate 
that the stability of L1P3V8 in both rat plasma and rat brain homogenate at 37 °C was significantly improved 
in comparison to that of P3V8. At the concentration of 2000 ng/mL, only 21% and 3% of P3V8 remained sta-
ble in plasma and brain homogenates, respectively, whereas nearly all L1P3V8 remained intact in plasma and 
around 45% of L1P3V8 could be detected in the brain homogenate after 1 hr of incubation. When the incubation 
was extended to 3 hr, around 87% and 21% of L1P3V8 were still detectable in the plasma and brain homogen-
ates, respectively, whereas P3V8 was almost completely degraded. Such improved stability of L1P3V8 was also 
observed in plasma when the experiments were repeated using 1000 ng/mL and 500 ng/mL of L1P3V8. Because 
the concentrations of both P3V8 and L1P3V8 after incubation at 500 ng/mL with brain homogenates were below 
the limit of quantitation (LOQ), no conclusion on comparison of their stabilities in brain homogenate could be 
drawn. Nonetheless, our results demonstrate that lipidation of P3V8 with palmitic acid significantly improved its 
stability in different biological matrices.
In vivo pharmacokinetic properties and brain uptake of P3V8 and L1P3V8. The plasma concen-
tration versus time profiles of P3V8 and L1P3V8 after intravenous administration at 3 μmol/kg in Sprague Dawley 
(SD) rats were studied and compared (Fig. 5a and Table 3). Without lipidation, P3V8 was quickly eliminated in 
the plasma 10 min after administration and its half-life was too short to be determined. In contrast, L1P3V8 had 
a significantly longer half-life of 17 min (Table 3) and remained quantifiable at 190 nmol/L in the plasma 90 min 
after dosing (Fig. 5a). The maximum observed drug concentration (Cmax) and integrated time-concentration 
responses (area under the curve, AUC) of L1P3V8 were also significantly higher than that of P3V8 (Table 3), indi-
cating better plasma stability after lipidation. The ability of P3V8 and L1P3V8 to be taken up by the brain was also 
analyzed after intravenous bolus injection. It was noticed that no P3V8 and 13 pmol/g L1P3V8 was detected in 
the rat brain 20 min after administration (Fig. 5b), suggesting that intravenous administration might not be suit-
able for brain delivery of these peptides. These undesirable pharmacokinetic properties led us to explore an alter-
native route of delivery of these peptides to the brain. One of the options is intranasal administration. Intranasal 
delivery involves the externally exposed olfactory or trigeminal nerve systems and thus is the most direct method 
of noninvasive delivery method to the brain27. Both P3V8 and L1P3V8 were administered intranasally into SD 
rats at a dose of 3 μmol/kg with pretreatment of 0.5% mucoadhesive chitosan. The pharmacokinetic profiles 
obtained are significantly different from those obtained after intravenous administration (Fig. 5c and Table 3). 
It was noted that the plasma levels of the intranasally administered inhibitors were significantly lower than that 
from intravenous administrations. The concentration of P3V8 in plasma peaked at 15 min and diminished rapidly 
within 20 min, whereas L1P3V8 concentration peaked at 18 min and remained stay around 9 nmol/mL at 90 min. 
Similar to the observations from intravenous administration, both Cmax and AUC of L1P3V8 were significantly 
higher than those of P3V8 after intranasal administration, which clearly demonstrates again that lipidation of the 
inhibitor increased its systemic exposure. In addition, significantly higher concentrations of L1P3V8 (58 pmol/g) 
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Figure 4. L1P3V8 effectively inhibits neurodegeneration induced by expanded CAG RNA in vitro and in vivo. 
(a) Chemical structure of L1P3V8. (b) Comparison of cellular uptake level of P3V8 and L1P3V8 in HEK293 
cells. Cellular uptake level was measured 3 hr after 100, 500 or 1000 nM treatment of respective peptide. The 
total amount of peptide in the cell lysate was normalized to total protein level in cell lysate. (c) Dose-dependent 
effect of synthetic L1P3V8 on the inhibition of cell death in EGFPCAG78 RNA-expressing HEK293 cells. Various 
amount of L1P3V8 were added into individual culture wells immediately after plasmid transfection. LDH 
cytotoxicity assay was performed. The IC50 value represents the concentration of peptides that reduced LDH 
enzyme activity by 50% when compared with the no peptide treatment control group. (c) Effect of L1P3V8 on 
suppressing DsRedCAG100 neurodegeneration in Drosophila. (d) Statistical analysis of panel (c). Pseudopupil 
assay was performed on 12 day-old adult flies. The flies were of genotypes w; gmr-GAL4 UAS-DsRedCAG0/+; 
+/+ and w; gmr-GAL4/+; UAS-DsRedCAG100/+. Data are expressed as mean ± S.E.M. for at least 3 independent 
experiments. *Indicates P < 0.05 and **indicates P < 0.01.
www.nature.com/scientificreports/
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and P3V8 (15 pmol/g) in the brain were achieved 20 min after intranasal dosing, as compared to those from 
intravenous administration, indicating better brain uptake via the intranasal route (Fig. 5d). Taken together, our 
findings support that the combined strategies of lipidation and intranasal administration significantly improve 
the pharmacokinetic properties and brain uptake of our peptide inhibitor.
Discussion
Despite our growing knowledge of the role of RNA transcripts in the pathological mechanisms of polyQ diseases, 
there is a lack of inhibitors that can counteract their neurotoxicity. On the basis that sequestration of NCL by 
expanded CAG RNA induces cytotoxicity, we recently developed a peptide inhibitor P3 that disrupts NCL-RNA 
Percentage of remained (%)
Incubation for 1 hr Incubation for 3 hr
Incubation Conc. 
(ng/mL) P3V8 L1P3V8 P3V8 L1P3V8
Plasma
2000 20.7 ± 3.3 98.8 ± 5.0*** <0.6# 86.9 ± 5.5
1000 8.6 ± 0.5 98.7 ± 3.9*** <1.3# 81.2 ± 1.5
500 <2.5# 88.1 ± 4.9 N/A 73.8 ± 5.7
Brain homogenate
2000 3.3 ± 0.6 45.0 ± 3.5*** <0.6# 21.2 ± 3.0
1000 4.0 ± 1.6 22.8 ± 1.2*** <1.3# 15.8 ± 0.7
500 <2.5# <20# N/A <20#
Table 2. Stability of P3V8 and L1P3V8 in different biological matrices after incubation at 37 °C. Data are 
presented as mean ± S.E.M. for 5 independent experiments. ***Indicates P < 0.001, significant difference 
compared with P3V8. #Indicates the concentration was below the lowest limit of quantification (12.5 ng/mL for 
P3V8 and 100 ng/mL for L1P3V8). N/A indicates not applicable.
Figure 5. In vivo pharmacokinetic study and brain uptake of 3 μmol/kg P3V8 or L1P3V8 in rats. (a) Inhibitor 
plasma concentration-time profiles of P3V8 and L1P3V8 following intravenous administration. (b) Brain 
concentrations of P3V8 (n.d.: not detected) and L1P3V8 at 20 min after intravenous administration (c) Inhibitor 
plasma concentration-time profiles of inhibitors administered via the intranasal route after pre-treatment with 
0.5% chitosan. (d) Brain concentrations of P3V8 and L1P3V8 at 20 min after intranasal administration. Data are 
presented as mean ± S.E.M. for 6 independent experiments. **Indicates P < 0.01.
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interaction and consequently mitigates RNA toxicity in polyQ diseases. In this study, we determined the equilib-
rium dissociation constant KD of P3 using ITC and discovered that the binding of P3 to RNA is both enthalpically 
and entropically favored. Short peptides like the 13-mer P3 usually assume flexible conformations in an aqueous 
solution and therefore suffer entropic loss upon binding to their targets. The finding that P3 binds expanded RNA 
with a favorable TΔS suggests that P3 may have undergone a conformation change upon binding to the RNA in 
solution.
When characterizing the effects of Ala substitutions of the pharmacophores of P3 on its interaction with 
expanded CAG RNA, we found that the basic Lys residues are more important than the aromatic residues in the 
interaction with expanded RNA. Substitution of any of the three Lys in P3 greatly reduced its binding affinity 
to RNA, indicating that electrostatic interactions play a dominant role in the affinity of P3. This is no surprise 
because CAG-repeat RNA duplex adopts an A’ helical conformation that is intermediate to the A- and B-forms 
of nucleic acids and is highly electronegative on its surface and thus charge-complementary with the key phar-
macophores of P3. As described above, the substitution of Lys at positions 3 and 5 by Arg remarkably improved 
the binding affinity of the peptide by nearly 10-fold (Table 1, P3V5). This observation suggests that the higher 
pKa of arginine and its guanidinium group may have further strengthened the ionic interaction with the RNA. 
Surprisingly, when we further mutated Lys13 to arginine, the binding affinity of the peptide was adversely reduced 
by nearly 3-fold, indicating that the amine group of Lys13, but not the charge alone, is critical for the binding of 
P3 and RNA. Further research is needed to investigate whether the side chain amine of Lys13 is important for 
stabilizing the peptide for RNA recognition or for mediating the critical interaction with nucleic acid.
Previous studies have shown that the charge neutralization of the N- and C-termini of synthetic peptides by 
acetylation and amidation can improve their stabilities in cell cultures and serum, thus improving their biological 
activity. Based on these findings, we generated P3V8, which is capped by acetylation and amidation at the N- and 
C-termini, respectively, in an attempt to improve the biological activity of P3 and in hopes that the same strategy 
can be applied to other P3 derivatives. We observed that capping of both termini of P3 not only improved its bind-
ing affinity to expanded CAG RNA (KD =0.33 µM) but also significantly improved its potency both in vivo and 
in vitro. In a recent study of compounds that block Alzheimer’s Aβ channel activity, Flora and colleagues showed 
that capping of the amine and carboxyl groups of free histidine helps to improve the residue activity by prevent-
ing nonspecific interaction with other reactive residues in the target28. We speculate that the capping of P3, now 
termed P3V8, might have exerted a similar effect and prevented nonspecific interaction between the peptide and 
the RNA’s negatively charged surface, thus improving the binding and efficacy of the peptide. Furthermore, the 
slight increase in pI of the peptide might also have contributed to its better affinity to the electrostatically negative 
surface of RNA (P3V8, pI = 10.02 vs. P3, pI = 9.64).
With the success of P3V8, we applied the same capping strategy to P3V5 to further improve its activity. 
However, as described above, the combination of Lys-to-Arg mutations of residues 3 and 5 and the capping of the 
peptide termini did not improve the peptide’s binding affinity but instead reduced the KD to about 2.3 µM. We 
speculate that upon N- and C-termini modifications, the interactions of the arginines and RNA might have been 
altered and that P3V9 likely adopts a different binding mode than P3V5 or P3V8. Moreover, the lengths of the 
basic side chains at residues 3 and 5 also appear to play a determining role in the binding of the peptide, as either 
lengthening or shortening the basic side chains abolished the interaction between the inhibitors and expanded 
RNA, suggesting that the distances between the basic side chains and the RNA is critical and that only limited 
conformational flexibility is allowed after P3V8 binds to the RNA. Such a rigid binding mode of P3V8 is fur-
ther supported by the observation that tandem repeats of the peptide failed to interact with the expanded RNA. 
Studies on the conformation and dynamics of P3V8 before and after RNA binding are needed to understand the 
mechanism of its specific inhibitory activity.
RNAs are becoming more recognized as attractive therapeutic targets because they fold into well-defined 
secondary and tertiary structures but exhibit a large variety of conformations, which can provide favorable oppor-
tunities for specific drug targeting. One interesting feature of the A’ form of CAG RNA is the widened major 
groove caused by the non-canonical AA base pairs29. Such widening provides binding sites that are unique to 
CAG-repeat RNA, and their accessibility may offer opportunity to improve the potency and specificity of our 
inhibitor. Further structural information on the interaction between P3V8 and CAG RNA will be useful to pro-
vide insight into how to make use of such a unique feature. Nevertheless, the results of our study demonstrates 
that neutralization of the N- and C-termini by simple modifications like acetylation and amidation can have 
significant effects on the binding and inhibitory properties of peptidyl inhibitor against an RNA target.
Intravenous administration
Intranasal administration  
(Pre-treated with 0.5% chitosan)
P3V8 L1P3V8 P3V8 L1P3V8
Cmax (nmol/L) 452 ± 22 10394 ± 1225*** 12 ± 2 74 ± 13***
Tmax (min) 2 ± 0 2 ± 0 15 ± 4 18 ± 1
AUC0-last (min * nmol/L) 1212 ± 80 179470 ± 18874*** 85 ± 32 2277 ± 558***
T1/2 (min) N/A 17 ± 4 N/A 37 ± 5
Table 3. Comparison of pharmacokinetic parameters of P3V8 and L1P3V8 after intravenous or intranasal 
administrations at 3 μmol/kg. Data are presented as mean ± S.E.M. for 6 independent experiments. ***Indicates 
P < 0.001, significant difference compared with P3V8. N/A indicates the parameter is not applicable due to 
insufficient time points with detectable plasma concentrations in elimination phase.
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In the past few decades, several inhibitors targeting protein toxicity30–33 or CAG RNA toxicity21,34 in polyQ 
disease have been developed. Some even showed therapeutic potential30–33. In this study, we demonstrated for the 
first time a structural activity relationship (SAR) investigation of the peptidylic inhibitor, P3, toward CAG RNA 
toxicity in polyQ diseases. The SAR study led us to identify a more potent peptide derivative of P3, P3V8, which 
shows dramatically improved inhibitory efficacy against expanded RNA-mediated toxicity in vivo. However, 
many peptides have short half-life in vivo, typically in minutes, which raises concern whether P3V8 could be 
administered as a therapeutic agent. Previous studies have established that covalent anchoring of lipids to pep-
tides promotes peptide binding to the fatty acid binding sites on albumin35. As albumin has a very long half-life, 
this ‘docking’ into albumin can significantly extend the functional half-life of peptides. Furthermore, we specu-
lated that lipidation of a peptide could improve the ability to cross cell membranes and enter cells. We therefore 
lipidated P3V8 by N-acylation with palmitic acid. Stability studies of the lipidated peptide L1P3V8 in plasma 
and brain homogenates revealed that lipidation significantly enhanced the cellular uptake and in vivo stability 
of P3V8. Above all, the lipidation strategy notably improved the pharmacokinetic profile and brain uptake of 
L1P3V8 in rats when it was administered intranasally, conferring our inhibitor drug/lead-like properties. The 
ability of therapeutic agents to pass the blood-brain-barrier is one of the most critical requirements for treatment 
of neuronal diseases. Although the mechanism of brain uptake of L1P3V8 remains to be elucidated, our results 
illustrate that the combination of lipidation and intranasal administration may provide a new means to improve 
the brain uptake of therapeutic agents. In conclusion, our results provide proof of concept that lipidated peptidyl 
inhibitors that target RNA toxicity are a novel therapeutic option for polyQ diseases. Further modification and 
optimization on this lead-like L1P3V8 will be needed to prolong its half-life and uptake level in the brain.
Methods
Peptide modeling. Molecular modeling of P3V8 was carried out using the online PEP-FOLD 2.0 server23. 
The sequence of the 13 amino acid peptide was submitted to the server and 100 simulations were performed using 
the default settings. The program returned the most representation conformations identified in terms of energy 
and population, and clustered them based on their sOPEP (Optimized Potential for Efficient structure Prediction) 
coarse grained energies. The representative model of the top-ranked cluster with the lowest sOPEP energy values 
was selected for this study.
Construction of plasmids. The pcDNA3.1-MJDCAG27, pcDNA3.1-MJDCAG78, pcDNA3.1-MJDCAA/G78 and 
pEGFPCAG78 constructs were reported previously7,13.
Synthesis of peptides and CAG RNAs. P3WT and P3 mutant (MT) peptides were purchased from 
GenScript USA Inc. All other peptide variants were prepared by Fmoc solid-phase peptide synthesis on automated 
peptide synthesizers, Biotage Syro Wave and Biotage SP Wave instruments, and assembled on a 0.1 mmol scale, 
unless noted otherwise. Peptide syntheses were carried out on a TentaGel S Rink Amide resin (0.22 mmol/g). 
Amino acids had Fmoc protection of Nα-amino groups; side-chain protecting groups were tert-butyl (Tyr, Glu, 
Asp), 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf, for Arg and hArg), and tert-butyloxycarbonyl 
(Boc, for Lys, Orn and Dap). Amino acids, NMP, DMF and piperidine were supplied by Iris Biotech (Germany). 
Acetonitrile, formic acid, triethylsilane (TES), trifluoroacetic acid (TFA) acetic anhydride, and dichlorometh-
ane (DCM) were from Sigma-Aldrich (Denmark). All chemicals were used as received and without further 
purification.
Analytical HPLC was performed with a Dionex Ultimate 3000 instrument on a Phenomenex Germini-NX 
C18 column (3 μm, 50 × 4.6 mm), column oven thermostated to 42 °C, and a linear gradient flow of CH3CN-H2O 
(0.1% formic acid), connected to an ESI-MS (MSO Plus Mass Spectrometer, Dionex). Purification of the peptide 
was performed on a preparative Dionex Ultimate 3000 HPLC with a C18 column Phenomenex Gemini Axia 
(5 μm, 100 × 21.2 mm, 110 Å). Unless otherwise stated CH3CN-H2O (0.1% TFA or 0.1% formic acid) was used as 
eluent with a flow of 15 mL/min. Gradient elution for 0–5 min was 5%, then to 55% for 5–32 min.
All standard Fmoc amino acids were coupled in DMF with 5.2 equivalents of amino acids and HOAt, with 
5 equivalents of HBTU and 9.4 equivalents DIEA. The coupling time was 60 min at room temperature. All 
non-standard amino acids, as well as palmitic acid, were coupled using 2 equivalents of amino acids and HOAt, 
1.9 equivalents of HBTU and 3.6 equivalents DIEA. Coupling times were 10 min at 75 °C. N-terminal fatty acid 
was introduced using the same conditions as for the coupling of standard amino acids.
In the synthesis of peptides P3V7 to P3V21, the first 10 couplings used a coupling time of 60 min at 25 °C with 
NMP and washings in-between couplings. Deprotections were performed by treatment with piperidine-DMF 
(2:3) for 3 min, followed by piperidine-DMF (1:4) for 15 min. After each coupling and deprotection, a washing 
procedure with NMP (3x), DCM (1x), then NMP (3x) was performed. From the 10th coupling onwards, the 
coupling time was increased to 2 × 120 min and an extra deprotection step (15 min) with piperidine-DMF (1:4) 
was added. The N-terminal acetylation was achieved with acetic anhydride in DMF (1:4) for 2 × 15 min. After 
completion of peptide chain assembly, the resin was washed 6 times with DCM. All the peptides were released 
and deprotected by treatment with a cocktail of trifluoroacetic acid (TFA), triethylsilane (TES) and H2O (95:2:3 
or 95:2.5:2.5) for 2 hr. The TFA solutions were concentrated under a flow of nitrogen and the compounds were 
precipitated with diethylether to yield the crude products. All peptides were purified by RP-HPLC.
The sequences of peptides are listed in Table 1, Supplementary Tables S1 and S2. The purity of peptides used 
in cell experiments and in vitro binding was over 90%. Desalted peptides were used in Drosophila feeding assays. 
All RNAs were synthesized using the MEGAscript® kit (Ambion) as previously described13, and the MJDCAG27, 
MJDCAG78 and MJDCAA/G78 RNAs were transcribed from linearized pcDNA3.1-MJDCAG constructs36.
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Isothermal titration calorimetry binding assay. Experiments were carried out using a MicroCal 
iTC200 isothermal titration calorimeter (GE Healthcare) at 25 °C. Data were analyzed using the Origin® scien-
tific plotting software version 7 (Microcal Software Inc.). All RNAs and peptides were dissolved in binding buffer 
(20 mM MOPS, pH 7.0; 300 mM NaCl) and 0.7 mM of peptide was titrated into 0.5 µM of RNA for each experi-
ment. The concentration of RNA was estimated with appropriate extinction coefficients at 260 nm on a Nanodrop 
2000 (Thermo Scientific). A reference power of 8 μcal/s was used with an initial 0.5 µl of injection of peptide fol-
lowed by 2 µl for all subsequent titrations points with a 60 sec initial equilibrium delay and 150 sec pause between 
injections. The samples were stirred at a speed of 1000 rpm throughout the experiment. The thermal titration 
data were fitted to the ‘one binding site model’ to determine the dissociation constant (KD). Each experiment was 
repeated at least 3 times with consistent results obtained.
Cell culture, plasmid transfection and peptide transfection. HEK293 cells were cultured at 37 °C 
with 5% CO2 in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. Primary rat cortical neu-
rons were isolated and cultured as previously described37. Transient transfection of HEK293 cells was performed 
using Lipofectamine 2000 (Life Technologies). P3V8 were delivered to HEK293 cells using the DeliverX (DX) 
Peptide Transfection Kit (Affymetrix) 4 hr after DNA transfection. At least two batches of independently synthe-
sized peptides were used in the experiments.
Lactate dehydrogenase (LDH) cytotoxicity assay and IC50 determination. To detect the effect 
of P3V8 and lipidated P3V8 (L1P3V8) on inhibiting cell death in EGFPCAG78 RNA-expressing HEK293 cells, a 
LDH assay was employed. HEK 293 cells were seeded on a 24-well plate at a density of 0.5 × 105, and pEGFP-
CAG78 DNA construct was used to transfect the cells. For P3V8 treatment, different concentrations of P3V8 as 
indicated in the figure were transfected by DeliverX transfectant 4 hr after DNA transfection. For L1P3V8 treat-
ment, different concentrations of L1P3V8 were added into individual wells immediately after DNA transfection. 
Seventy-two hours after treatment, LDH enzyme activity in the cell culture medium was measured as described 
before. Experimental groups were normalized to the untransfected control. After normalization, data were ana-
lyzed using the dose response-inhibition curve (nonlinear regression-variable slope) to determine the IC50 value 
(Prism6 software, GraphPad Software, Inc.). Each experiment was repeated at least 3 times.
Drosophila genetics, peptide feeding and assays. Flies were raised at 21.5 °C on cornmeal medium 
supplemented with dry yeast. Fly lines bearing UAS-DsRedCAG0 and UAS-DsRedCAG100 were kind gifts of Professor 
Nancy Bonini (University of Pennsylvania, USA). The gmr-GAL4 fly line was obtained from Bloomington 
Drosophila Stock Center. For pseudopupil assay, third instar larvae were fed with various amount of respective 
peptides dissolved in 2% sucrose solution for 2 hr and then continued to culture in standard fly food at 21.5 °C38. 
Pseudopupil assay was performed on 12 day-old adult flies as mentioned previously39. Images were captured by 
SPOT Insight CCD camera controlled by the SPOT Advanced software (Diagnostic instruments Inc.). Image 
processing was performed using the Adobe Photoshop CS software (Adobe). Each experiment was repeated at 
least 3 times (n = 10 fly heads), and consistent results were obtained. For viability test of wild-type flies from egg 
to adult stage, eggs born within 5 hr were collected and cultured in fly food containing 10 or 50 μM of respective 
peptides at 21.5°C. Viability from egg-to-adult was calculated as the number of adult flies collected divided by the 
number of eggs examined. Each experiment was repeated for three times (at least 130 eggs were examined in each 
group). Two batches of independently synthesized peptides were used in the experiments.
RNA extraction, reverse transcription-PCR and real-time PCR. RNA was extracted from cells or 
ten 12 day-old adult fly heads by Trizol reagent (Life Technologies), and 1 μg of purified RNA was then used for 
reverse-transcription using the ImPromII™ Reverse Transcription System (Promega). Random hexamer (Roche) 
was used as primers in reverse transcription. Taqman gene expression assays were performed on an ABI 7500 
Real-time PCR system and data were analyzed as previously described13. The following probes were used: pre-45s 
rRNA (Assay ID: AILJIZM), pre-rRNA (Assay ID: AIMSG5U), Drosophila GAPDH (Assay ID: Dm01841186) and 
human actin (Assay ID: Hs99999903_m1). Each experiment was repeated at least 3 times.
In vitro stability studies in rat plasma and brain homogenate. Sprague-Dawley (SD) rats (male, 
180–200 g) were supplied by the Laboratory Animal Services Centre at The Chinese University of Hong Kong. All 
animal studies were conducted under the approval of the Animal Ethics Committee of The Chinese University of 
Hong Kong, and were performed in accordance with relevant guidelines and regulations. Blank rat brain homoge-
nate was prepared by ultrasonic probe homogenization (Micoson XL-2000, Misonix, Framingdale, NY, USA) of 
brains collected from the control rats. Blank rat plasma was prepared by centrifugation (8000 rcf for 3.5 min) of 
blood collected from control rats. For the stability test, 2000 ng/mL and 500 ng/mL of P3V8 or L1P3V8 was spiked 
into the blank rat plasma or brain homogenate and vortexed. The mixtures were incubated at 37 °C with 100 rpm 
in a water bath for 1 or 3 hr. The incubation was terminated by addition twice the volume of acetonitrile and cen-
trifugation at 13000 rcf for 10 min. The supernatant was collected for LC/MS/MS analysis.
Cellular uptake studies in HEK293 cells. HEK293 cells were seeded on a 6-well plate at a den-
sity of 6 × 105 and cultured overnight at 37 °C with 5% CO2 in DMEM supplemented with 10% FBS and 1% 
penicillin-streptomycin. Cells were then treated with 100, 500 or 1000 nM of respective peptide at 37 °C for 3 hr. 
After treatment, the cells were washed with ice-cold PBS and then lysed by 2% SDS solution. Aliquot (100 µl) of 
the cell lysate was added with 200 µl acetonitrile and centrifuged at 13000 rcf for 10 min to precipitate the proteins. 
The collected supernatant was subjected to LC/MS analysis. The protein concentration of the cell lysate was meas-
ured using a bicinchoninic acid protein assay kit following Sigma’s protocol.
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Plasma pharmacokinetic and brain uptake studies in SD rat. SD rats (180–200 g) were anesthetized 
with an intraperitoneal injection of ketamine (60 mg/kg) and xylazine (6 mg/kg) and received a minor surgery of 
cannulation with a polythene tube (0.4 mm i.d., 0.8 mm o.d., Harvard Apparatus, Holliston, MA, USA) in the left 
jugular vein. The rats received an overnight recovery with free access to food and water. In the following day, rats 
were administered P3V8 or L1P3V8 (3 μmol/kg) via intravenous or intranasal routes. For intravenous adminis-
tration, appropriate volume of P3V8 or L1P3V8 (3 μmol/mL, dissolved in water) was injected to the rats via the 
cannula. For intranasal administration, the rats were temporarily anesthetized by inhalation of carbon dioxide, 
and was administrated with appropriate volume of P3V8 or L1P3V8 (30 μmol/mL, dissolved in water with 5% 
PEG400) in both nostrils by a micropipette. Chitosan solution (0.5% w/v, pH 6.5, 20 μL) was pre-treated to rats 
intranasally 5 min before the P3V8 and L1P3V8 was administrated via intranasal routes. For the pharmacokinetic 
study, after the drug administration, blood samples were collected from the catheter at appropriate time intervals 
(2, 5, 10, 15, 20, 30, 45, 60, and 90 min). After each collection, 0.2 mL of saline containing 25 IU heparin was 
injected to compensate for the blood loss. Plasma was collected after centrifugation at 8000 rcf for 3.5 min and 
stored at −80°C until analysis. For brain uptake study, at 20 min, the rat was anesthetized and perfused by 500 mL 
saline, and the whole brain was collected. The brain was wiped by tissue paper to remove excess water, meninges 
and blood vessels followed by storage at −80 °C until analysis.
Sample preparation for LC/MS/MS. Aliquot of plasma sample (80 μL) was mixed with 160 μL acetonitrile. 
The mixture was vortexed for 1 min and followed by centrifugation at 13000 rcf for 10 min. The supernatant was 
collect and subjected to LC/MS/MS analysis.
To prepare brain homogenate, the whole brain of each rat was minced. Saline (2 mL/g brain) was added fol-
lowed by ultrasonic probe homogenization on ice. For analysis of P3V8, aliquot of brain homogenate (100 μL) 
was mixed with 200 μL acetonitrile. The mixture was vortexed for 1 min and followed by centrifugation at 13000 
rcf for 10 min to collect the supernatant. For analysis of L1P3V8, aliquot of brain homogenate (650 μL) was centri-
fuged at 6000 rcf for 10 min. After the supernatant was collected, 400 μL saline was added to re-suspend the pellet. 
The mixture was again vortexed for 5 min and centrifuged at 6000 rcf for 10 min. The supernatant collected was 
loaded to a preconditioned Oasis® HLB cartridges (Waters, MA, USA). After washed with 1 mL of 10% acetoni-
trile in water, the analyte was eluted with 0.25 mL 95% acetonitrile in water.
LC/MS/MS analysis. Agilent 6430 Triple Quadrupole LC/MS/MS system (Agilent Technologies, CA, USA) 
was employed for the analysis. For analysis of P3V8, chromatographic separation was achieved on a SunFire C8 
Column (250 mm × 4.6 mm, 5 µm). The mobile phase of water containing 0.2% formic acid (A) and acetonitrile 
(B) was used with a gradient elution (0–5 min, 20–70% B). The flow rate was 0.8 mL/min. Multiple reactions 
monitoring (MRM) with fragmentation transition of 500 to 129 in positive ion mode was employed for quanti-
zation of P3V8. For analysis of L1P3V8, Alltima Amino Alltech Column (250 mm × 4.6 mm, 5 µm) was used for 
separation. Mobile phase of water (A) and acetonitrile (B) was used. The gradient elution for plasma samples was 
0–4 min, 30–95% B, and for brain samples was 0–9 min, 10–95% B. The flow rate was 0.8 mL/min. MRM transi-
tion of 565 to 88 in positive ion mode was used for quantization of L1P3V8.
Data analyses. Plasma concentration verse time profiles were analyzed by WinNonlin (Pharsight 
Corporation, Mountain View, CA, USA, Version 2.1) to obtain the pharmacokinetics parameters. Other data 
were analyzed by one-way ANOVA followed by post hoc Tukey test or unpaired t-test. “*”, “**”, “***” and “****” 
represent P < 0.05, P < 0.01, P < 0.001 and P < 0.0001 respectively, which are considered statistically significant.
References
 1. Orr, H. T. & Zoghbi, H. Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575–621 (2007).
 2. Sakahira, H., Breuer, P., Hayer-Hartl, M. K. & Hartl, F. U. Molecular chaperones as modulators of polyglutamine protein aggregation 
and toxicity. Proc. Natl. Acad. Sci. USA 99(Suppl 4), 16412–16418 (2002).
 3. Takahashi, T., Katada, S. & Onodera, O. Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we 
going? J. Mol. Cell. Biol. 2, 180–191 (2010).
 4. Michalik, A. & Van Broeckhoven, C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum. Mol. Genet. 12(Spec No. 
2), R173–86 (2003).
 5. Fiszer, A. & Krzyzosiak, W. J. RNA toxicity in polyglutamine disorders: concepts, models, and progress of research. J. Mol. Med. 
(Berl) 91, 683–691 (2013).
 6. Fiszer, A. & Krzyzosiak, W. J. Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res. 42, 6787–6810 
(2014).
 7. Li, L. B., Yu, Z., Teng, X. & Bonini, N. M. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 453, 
1107–1111 (2008).
 8. Marti, E. RNA toxicity induced by expanded CAG repeats in Huntington’s disease. Brain Pathol. 26, 779–786 (2016).
 9. de Mezer, M., Wojciechowska, M., Napierala, M., Sobczak, K. & Krzyzosiak, W. J. Mutant CAG repeats of Huntingtin transcript fold 
into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res. 39, 3852–3863 (2011).
 10. Mykowska, A., Sobczak, K., Wojciechowska, M., Kozlowski, P. & Krzyzosiak, W. J. CAG repeats mimic CUG repeats in the 
misregulation of alternative splicing. Nucleic Acids Res. 39, 8938–8951 (2011).
 11. Krol, J. et al. Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol. Cell 25, 575–586 (2007).
 12. Banez-Coronel, M. et al. A pathogenic mechanism in Huntington’s disease involves small CAG-repeated RNAs with neurotoxic 
activity. PLoS Genet. 8, e1002481 (2012).
 13. Tsoi, H., Lau, T. C., Tsang, S. Y., Lau, K. F. & Chan, H. Y. CAG expansion induces nucleolar stress in polyglutamine diseases. Proc. 
Natl. Acad. Sci. USA 109, 13428–13433 (2012).
 14. Tsoi, H. & Chan, H. Y. Expression of expanded CAG transcripts triggers nucleolar stress in Huntington’s disease. Cerebellum 12, 
310–312 (2013).
 15. James, A., Wang, Y., Raje, H., Rosby, R. & DiMario, P. Nucleolar stress with and without p53. Nucleus 5, 402–426 (2014).
 16. Wang, D. B., Kinoshita, C., Kinoshita, Y. & Morrison, R. S. P53 and Mitochondrial Function in Neurons. Biochim. Biophys. Acta 
1842, 1186–1197 (2014).
 17. Zhang, Y. & Lu, H. Signaling to p53: ribosomal proteins find their way. Cancer. Cell. 16, 369–377 (2009).
www.nature.com/scientificreports/
13SCieNTifiC REPORTS | 7: 12077  | DOI:10.1038/s41598-017-11695-y
 18. Rickards, B., Flint, S. J., Cole, M. D. & LeRoy, G. Nucleolin is required for RNA polymerase I transcription in vivo. Mol. Cell. Biol. 27, 
937–948 (2007).
 19. Ginisty, H., Amalric, F. & Bouvet, P. Nucleolin functions in the first step of ribosomal RNA processing. EMBO J. 17, 1476–1486 (1998).
 20. Bouvet, P., Diaz, J. J., Kindbeiter, K., Madjar, J. J. & Amalric, F. Nucleolin interacts with several ribosomal proteins through its RGG 
domain. J. Biol. Chem. 273, 19025–19029 (1998).
 21. Zhang, Q. et al. Assessing a peptidylic inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- 
and protein-mediated toxicities in patient cells and Drosophila. Dis. Model. Mech. 9, 321–334 (2016).
 22. Fujiwara, Y. et al. Structure and function of the N-terminal nucleolin binding domain of nuclear valosin-containing protein-like 2 
(NVL2) harboring a nucleolar localization signal. J. Biol. Chem. 286, 21732–21741 (2011).
 23. Shen, Y., Maupetit, J., Derreumaux, P. & Tuffery, P. Improved PEP-FOLD Approach for Peptide and Miniprotein Structure 
Prediction. J. Chem. Theory Comput. 10, 4745–4758, http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/ (2014).
 24. Knudsen, L. B. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily 
administration. J. Med. Chem. 43, 1664–1669 (2000).
 25. Madsen, K. et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of 
fatty acid length, polarity, and bulkiness. J. Med. Chem. 50, 6126–6132 (2007).
 26. Oh, D. et al. Enhanced cellular uptake of short polyarginine peptides through fatty acylation and cyclization. Mol. Pharm. 11, 
2845–2854 (2014).
 27. Mittal, D. et al. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 21, 75–86 (2014).
 28. Arispe, N., Diaz, J. C. & Flora, M. Efficiency of histidine-associating compounds for blocking the alzheimer’s Abeta channel activity 
and cytotoxicity. Biophys. J. 95, 4879–4889 (2008).
 29. Tawani, A. & Kumar, A. Structural Insights Reveal the Dynamics of the Repeating r(CAG) Transcript Found in Huntington’s Disease 
(HD) and Spinocerebellar Ataxias (SCAs). PLoS One 10, e0131788 (2015).
 30. Popiel, H. A. et al. The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative 
Diseases. J. Amino Acids 2011, 265084 (2011).
 31. Mishra, R. et al. Inhibiting the nucleation of amyloid structure in a huntingtin fragment by targeting alpha-helix-rich oligomeric 
intermediates. J. Mol. Biol. 415, 900–917 (2012).
 32. Kazantsev, A. et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. 
Nat. Genet. 30, 367–376 (2002).
 33. Arribat, Y. et al. A huntingtin peptide inhibits polyQ-huntingtin associated defects. PLoS One 8, e68775 (2013).
 34. Kumar, A. et al. Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by 
expanded r(CAG)-containing transcripts. ACS Chem. Biol. 7, 496–505 (2012).
 35. van Witteloostuijn, S. B., Pedersen, S. L. & Jensen, K. J. Half-Life Extension of Biopharmaceuticals using Chemical Methods: 
Alternatives to PEGylation. ChemMedChem 11, 2474–2495 (2016).
 36. Tsoi, H., Lau, C. K., Lau, K. F. & Chan, H. Y. Perturbation of U2AF65/NXF1-mediated RNA nuclear export enhances RNA toxicity 
in polyQ diseases. Hum. Mol. Genet. 20, 3787–3797 (2011).
 37. Lau, K. F. et al. Dexras1 interacts with FE65 to regulate FE65-amyloid precursor protein-dependent transcription. J. Biol. Chem. 283, 
34728–34737 (2008).
 38. Chau, K. W., Chan, W. Y., Shaw, P. C. & Chan, H. Y. Biochemical investigation of Tau protein phosphorylation status and its solubility 
properties in Drosophila. Biochem. Biophys. Res. Commun. 346, 150–159 (2006).
 39. Wong, S. L., Chan, W. M. & Chan, H. Y. Sodium dodecyl sulfate-insoluble oligomers are involved in polyglutamine degeneration. 
FASEB J. 22, 3348–3357 (2008).
Acknowledgements
This work was supported by the ANR/RGC Joint Research Scheme (A-CUHK401/14) and Collaborative 
Research Fund (CUHK1/CRF/13G) of the Hong Kong Research Grants Council; CUHK Lui Che Woo Institute 
of Innovative Medicine BRAIN Initiative (8303404); CUHK Group Research Scheme (3110102); CUHK 
Technology and Business Development Fund (TBF16SCI008); CUHK Vice-Chancellor’s One-Off Discretionary 
Fund (VCF2014011); CUHK One-off Funding for Joint Lab/Research Collaboration (3132980); CUHK Gerald 
Choa Neuroscience Centre (7105306); and donations from Chow Tai Fook Charity Foundation (6903898) and 
Hong Kong Spinocerebellar Ataxia Association (6903291).
Author Contributions
Q.Z., H.Y.E.C., and J.C.K.N. conceived the study, analyzed the data and wrote the paper. Q.Z., Y.A., S.H.P., and Y.M. 
performed assays to analyze the inhibitory activities of peptides in vitro and in vivo. K.K.S., C.S.M., J.T.B. and K.J.J. 
designed, synthesized and purified the peptides. M.Y., Q.Z., and Z.Z. performed the in vitro stability and cell uptake, 
in vivo pharmacokinetics and sample analyses by LC/MS/MS. K.J.J., Z.Z., H.Y.E.C., and J.C.K.N. designed the peptides 
and experiments, and supervised the study. All authors contributed to discussions and reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-11695-y
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
